Key facts
- It has raised $28.1M; the latest was Later Stage VC in Mar 2025.
- Notable investors include Cowin Capital, TusStar Incubator, Source Code Capital, Tsinghua Innovation Ventures, Beijing Delian Yuntong Investment Management Company — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for CellBri Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for CellBri Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CellBri Biotechnology
Developer and provider of cell and gene therapy instrument manufacturing solutions intended to bring carrier genetic test (CGT) industrial instruments to key upstream manufacturing companies. The company's solutions focus on the field of cell therapy and source technology innovation and produces closed, automated, digital and flexible CGT industrial instruments to complete a variety of cell processing tasks across different cell types, enabling the healthcare industry to accurate and efficiently engage in clinical processes that involve PBMC separation, magnetic based incubation and washing, viral transduction, concentrated cell harvest, cell washing and dispending.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2020
- Website
- cellbri.com/
- Ownership
- Privately Held (backing)
CellBri Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CellBri Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CellBri Biotechnology in its N-PORT filings yet. We sweep new filings monthly.